GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regenicin RGIN · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

About Regenicin

Its shares trade under the ticker RGIN. It has been listed since 12 May 2008.

Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The company is headquartered in Little Falls, New Jersey. The company went IPO on 2008-05-12. The firm is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. The company is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
12 May 2008
Employees
3

Leadership

Pay as last reported

  • Mr. Randall McCoyChief Executive Officer, Director, since 2010$250,000
  • Mr. John WeberChief Financial Officer, Director, since 2010$125,000
  • Dr. J. Roy NelsonChief Science Officer$150,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Regenicin's NovaDerm provides multi-layered tissue-engineered skin for burns and chronic wounds treatment.
  • TempaDerm offers cryo-preserved cell banks for continuous supply of non-allogenic skin substitutes.
  • The company focuses on regenerative cell therapies for damaged tissues and organs restoration.

Weaknesses

  • Regenicin employs only 3 full-time employees, limiting operational capacity.
  • The company's IPO in 2008 may indicate limited market traction or funding challenges.
  • Regenicin's product development is concentrated on a narrow segment of skin treatments.

Opportunities

  • Expanding NovaDerm applications to plastic surgery procedures could increase market reach.
  • TempaDerm's use for chronic skin wounds presents a growing healthcare market opportunity.
  • Regenerative cell therapies in the US market show potential for increased adoption.

Threats

  • Regenicin faces competition from established biotechnology firms in the US market.
  • Regenerative medicine regulations could impose additional compliance costs.
  • Limited employee count may hinder rapid response to market changes or crises.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.